Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969643 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-LIV1A in Breast Cancer Patients
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
NCT01969643: Completed Phase 1 study, sponsored by Seagen.
NCT01969643 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 290 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (383% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01969643, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
Study Summary
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
Primary Outcome
An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Interventions
- DRUG Trastuzumab
- DRUG ladiratuzumab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2013-10-22 |
| Est. Completion | 2023-02-04 |
| Phase | Phase 1 |
What the finished NCT01969643 record still lists
NCT01969643 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (383% higher).
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT01969643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01969643 about?
NCT01969643 is a clinical study titled "A Safety Study of SGN-LIV1A in Breast Cancer Patients". This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
What is the current status of trial NCT01969643?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2013-10-22. Estimated completion is 2023-02-04.
What interventions are being tested in trial NCT01969643?
The interventions under investigation include: Trastuzumab (DRUG), ladiratuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT01969643?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01969643's enrollment target sits among peer trials
290 138th of 2000 higher than 1,862 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI